3 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMOCompleted
The primary endpoint of this feasibility study is the technical success of positioning the SLIDE device to verify the speed and ease of use without unexpected device related adverse events. A technical success is defined that the SLIDE device was…
Approved WMOCompleted
To assess the immunomodulatory effects of erythromycin and clindamycin in healthy volunteers.